On Friday, Shares of Weatherford International plc (NYSE:WFT), lost -2.51% to $13.19.
Weatherford International plc, declared that it has been selected to be comprised of in the broad-market Russell 3000® Index. This inclusion will be effective upon the close of trading on June 26, 2015, when the Russell Investment Group reconstitutes its comprehensive set of U.S. and global equity indexes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. About $5.7 trillion in assets are benchmarked to the Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Predictions:
18 analysts have set the short term price target of Weatherford International plc (NYSE:WFT) at $16.86. The standard deviation of short term price target has been estimated at $3.49, implying that the actual price may fluctuate by this value. The higher and the lower price estimates are $ 24 and $12 respectively.
On Jul 24, 2014, the shares registered one year high at $24.88 and the one year low was seen on Jan 15, 2015.
Weatherford International public limited company provides equipment and services used in the drilling, evaluation, completion, production, and intervention of oil and natural gas wells worldwide.
Shares of Fiat Chrysler Automobiles N.V. (NYSE:FCAU), declined -1.49% to $15.19, during its last trading session.
Fiat Chrysler Automobiles, was recognized by the National Business Group on Health (NBGH) for its comprehensive programs that enable a healthy workplace and encourage healthy lifestyles for both employees and families.
FCA US received the gold medal award for the seventh successive year. The Company is the only automaker to earn this award in the past five years.
The NBGH’s Best Employers for Healthy Lifestyles Award recognizes employers that have embraced a culture of wellness and are working collaboratively to improve their employees’ health, productivity and quality of life. FCA US was among 68 other groups that received the 2015 Best Employers for Healthy Lifestyles Award on June 17 at the National Business Group on Health’s Leadership Summit in Washington, D.C.
In 1985, the FCA US-UAW wellness program was created and implemented for both represented and non-represented employees and is focused on promoting a healthier workplace, healthy lifestyles and reducing the risk of illness and chronic disease. The program encompasses a wide range of services, counting health assessments, biometric screenings, workshops, campaigns and health coaching. Employee interest, health assessments, screening results and disability data assist decide program topics. Incentives linked to wellness activities are used to enhance employee participation.
Fiat Chrysler Automobiles N.V., an automotive group, designs, engineers, manufactures, distributes, and sells vehicles and components. It offers passenger cars, light trucks, and light commercial vehicles under the Abarth, Alfa Romeo, Chrysler, Dodge, Fiat, Fiat Professional, Jeep, Lancia, and Ram brand names, in addition to after-sales services and parts under the Mopar brand name.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 0.27% gain, and closed at $66.80.
Bristol-Myers Squibb Company, declared that the European Commission has approved Opdivo, a PD-1 immune checkpoint inhibitor, for the treatment of advanced (unresectable or metastatic) melanoma in adults, regardless of BRAF status. Recently’s approval allows for the marketing of Opdivo in all 28 Member States of the EU. It follows an accelerated assessment by the Committee for Medicinal Products for Human Use (CHMP), which was declared on April 24, 2015. This accelerated assessment was given because Opdivo qualified for the designation as a “medicinal product of major interest from the point of view of public health and in particular from the view point of therapeutic innovation.” Opdivo is the only PD-1 immune checkpoint inhibitor to receive an accelerated assessment in Europe, and is the first approval given by the European Commission for a PD-1 inhibitor in any cancer.
The incidence of melanoma has continued to enhance in almost all European countries, with an estimated one in five patients predictable to develop metastatic, or advanced, disease. Historically, prognosis for late-stage metastatic melanoma has been poor: the average survival rate for stage IV is just six months with a one-year mortality rate of 75%.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
